Tanios S. Bekaii-Saab, M.D.

1. Eslinger C, Walden D, McGary A, Emiloju O, Ahn D, Sonbol MB, Bekaii-Saab T, Zhu M, Hubbard J, Wu C. Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy. Cancer. 2025 Feb 15; 131 (4):e35756
   View PubMed
2. Chen C, Zhu M, Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A, eNRGy Investigators. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 6; 392 (6):566-576
   View PubMed
3. Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol 2025 Feb; 21 (3):303-311 Epub 2024 Dec 26
   View PubMed
4. Abidoye O, Ahn DH, Borad MJ, Wu C, Bekaii-Saab T, Chakrabarti S, Sonbol MB. Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer. Cells. 2025 Jan 22; 14 (3)
   View PubMed
5. Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025 Jan 17 [Epub ahead of print]
   View PubMed
6. Eslinger C, Seddighzadeh B, Yee C, Elsabbagh Z, Pai R, Hartley C, Starr J, Bekaii-Saab T, Halfdanarson TR, Sonbol MB. Clinical Outcomes and Molecular Profiling of Pancreatic Acinar Cell Carcinoma: A Retrospective Study. JCO Precis Oncol. 2025 Jan; 9:e2400450 Epub 2025 Jan 07
   View PubMed
7. Marell P, Kournoutas I, Gile J, Peersen A, Shah P, Babiker H, Kankeu LF, Washburn L, Graham R, Truty M, Starlinger P, Halfdanarson T, Jin Z, Jatoi A, McWilliams R, Borad M, Bekaii-Saab TS, Mahipal A, Ou FS, Tran NH. Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. Oncologist. 2024 Dec 14 [Epub ahead of print]
   View PubMed
8. Scalia IG, Sonbol MB, Farina JM, Pereyra M, Wang Y, Bekaii-Saab TS, Yang M, Connolly HM, Pellikka PA, Herrmann J, Halfdanarson TR, Starr JS, Luis SA, Arsanjani R, Ayoub C. Lutetium-177 DOTATATE Therapy and Cardiac Outcomes in Patients With Neuroendocrine Tumor and Cardiac Metastases. JACC CardioOncol. 2024 Dec; 6 (6):982-984 Epub 2024 Nov 12
   View PubMed
9. Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population. Oncologist. 2024 Oct 19 [Epub ahead of print]
   View PubMed
10. Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby RM, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko TK, Lopes G, Aggarwal C, Lee AI, Choueiri TK. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncol Pract. 2024 Oct 7; OP2400565 Epub 2024 Oct 07
    View PubMed
11. Mosalem O, Coston TW, Imperial R, Mauer E, Thompson C, Yilma B, Bekaii-Saab TS, Stoppler MC, Starr JS. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer. Oncologist. 2024 Sep 6; 29 (9):e1224-e1227
    View PubMed
12. Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. Eur J Cancer. 2024 Sep; 208:114199 Epub 2024 June 30
    View PubMed
13. Bekaii-Saab T, Khan N, Ostojic H, Jiao X, Chen G, Lin W, Bruno A. Real-world dosing of regorafenib and outcomes among patients with metastatic colorectal cancer: a retrospective analysis using US claims data. BMC Cancer. 2024 Aug 2; 24 (1):939 Epub 2024 Aug 02
    View PubMed
14. Paly VF, Dasari A, Hubbard J, Bekaii-Saab T, Padukkavidana T, Hernandez L. Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US. J Comp Eff Res. 2024 Aug; 13 (8):e240084 Epub 2024 July 08
    View PubMed
15. Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, Sabari JK, Peguero JA, Paulson AS, Janne PA, Cruz-Correa M, Anderes K, Velastegui K, Yan X, Der-Torossian H, Klempner SJ, Kopetz SE. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024 Jun 3; 14 (6):982-993
    View PubMed
16. Kusne Y, Lasho T, Finke C, Elsabbagh Z, McCue S, Hobday T, Starr J, Bekaii-Saab T, Halfdanarson TR, Patnaik MM, Ou FS, Sonbol MB. Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study. JCO Precis Oncol. 2024 Jun; 8:e2400143
    View PubMed
17. Bekaii-Saab TS, Barzi A, Cusnir M. Improving survival in metastatic colorectal cancer through optimized patient selection. Clin Adv Hematol Oncol. 2024 Jun; 22 Suppl 4 (5):1-20
    View PubMed
18. Bekaii-Saab TS. Real-world data on sequencing third-line therapies for metastatic colorectal cancer. Clin Adv Hematol Oncol 2024 Jun; 22 Suppl 4 (5):10-14
    View PubMed
19. Bekaii-Saab TS, Barzi A, Cusnir M. How best to extend overall survival in metastatic colorectal cancer: Q&A. Clin Adv Hematol Oncol 2024 Jun; 22 Suppl 4 (5):16-17
    View PubMed
20. Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2024 May 13; 16 (10)
    View PubMed
21. Wu C, Pai RK, Kosiorek H, Banerjee I, Pfeiffer A, Hagen CE, Hartley CP, Graham RP, Sonbol MB, Bekaii-Saab T, Xie H, Sinicrope FA, Patel B, Westerling-Bui T, Shivji S, Conner J, Swallow C, Savage P, Cyr DP, Kirsch R, Pai RK. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC. Clin Cancer Res. 2024 May 1; 30 (9):1811-1821
    View PubMed
22. Bekaii-Saab T. A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer. Am J Manag Care. 2024 May; 30 (2 Suppl):S23-S30
    View PubMed
23. Barzi A, Bekaii-Saab T. Sequencing considerations in the third-line treatment of metastatic colorectal cancer. Am J Manag Care. 2024 May; 30 (2 Suppl):S31-S35
    View PubMed
24. Ko AH, Coveler AL, Schlechter BL, Bekaii-Saab T, Wolpin BM, Clark JW, Bockorny B, Bai LY, Lin YC, Chiang E, Langecker P, Lin SY. A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer. Invest New Drugs. 2024 Apr; 42 (2):221-228 Epub 2024 Mar 05
    View PubMed
25. Chandana SR, Woods LM, Maxwell F, Gandolfo R, Bekaii-Saab T. Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J Cancer 198 (2024) 113471]. Eur J Cancer. 2024 Apr; 201:113941 Epub 2024 Mar 02
    View PubMed
26. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr; 20 (11):653-663 Epub 2023 Oct 10
    View PubMed
27. Strickler JH, Bekaii-Saab TS. A study to learn how well tucatinib plus trastuzumab works for treating participants with metastatic colorectal cancer, and how safe it is: a plain language summary of the MOUNTAINEER study. Future Oncol 2024 Mar; 20 (8):409-421 Epub 2023 Nov 08
    View PubMed
28. Chandana SR, Woods LM, Maxwell F, Gandolfo R, Bekaii-Saab T. Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. Eur J Cancer. 2024 Feb; 198:113471 Epub 2023 Dec 12
    View PubMed
29. Uson Junior PLS, Bekaii-Saab T. Act Local, Think Global: IR and Its Role in Immuno-Oncology in Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 Feb; 35 (2):173-177
    View PubMed
30. Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Katz MHG, Bauer TW, Nowak JA, Wolpin BM, Abrams TA, Patel A, Clancy TE, Wang J, Mancias JD, Reilley MJ, Stucky CH, Bekaii-Saab TS, Elias R, Merchant N, Slingluff CL Jr, Rahma OE, Dougan SK. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-kappaB Signaling in Patients with Pancreatic Cancer. Clin Cancer Res. 2024 Feb 1; 30 (3):542-553
    View PubMed
31. Aslam FN, Loveday TA, Junior PLSU, Truty M, Smoot R, Bekaii-Saab T, Stucky CC, Babiker H, Borad MJ. APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients. Ann Gastroenterol. 2024 Jan-Feb; 37 (1):95-103 Epub 2023 Dec 20
    View PubMed
32. Zheng-Lin B, Bekaii-Saab TS. Treatment options for HER2-expressing colorectal cancer: updates and recent approvals. Ther Adv Med Oncol. 2024; 16:17588359231225037. Epub 2024 Jan 18.
    View PubMed
33. Wainberg ZA, Bekaii-Saab T, O'Reilly E, Pant S. Starting at the front line in metastatic pancreatic cancers: as new options emerge, how do you select and sequence?. Oncology (08909091). 2024; 38 (9):352-4
    
34. Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol. 2023 Dec 20; 41 (36):5569-5578 Epub 2023 Sept 26
    View PubMed
35. Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, Bekaii-Saab TS, Elias R, Merchant N, Dias Costa A, Lenehan P, Cardot-Ruffino V, Rodig S, Pfaff K, Dougan SK, Nowak JA, Varadhachary GR, Slingluff CL, Rahma O. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma. J Immunother Cancer. 2023 Dec 1; 11 (12) Epub 2023 Dec 01
    View PubMed
36. Caughey BA, Umemoto K, Green MF, Ikeda M, Lowe ME, Ueno M, Niedzwiecki D, Taniguchi H, Walden DJ, Komatsu Y, D'Anna R, Esaki T, Denda T, Datto MB, Bando H, Bekaii-Saab T, Yoshino T, Strickler JH, Nakamura Y. Identification of an optimal mutant allele frequency to detect activating KRAS, NRAS, and BRAF mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomas. J Gastrointest Oncol. 2023 Oct 31; 14 (5):2083-2096 Epub 2023 Sept 19
    View PubMed
37. Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardiere C, Dean A, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab T, Pant S, Hubner RA, Xiao Z, Chen H, Benzaghou F, O'Reilly EM. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7; 402 (10409):1272-1281 Epub 2023 Sept 11
    View PubMed
38. Bekaii-Saab TS, Lach K, Hsu LI, Siadak M, Stecher M, Ward J, Beckerman R, Strickler JH. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. Oncologist. 2023 Oct 3; 28 (10):885-893
    View PubMed
39. Zheng-Lin B, Graham RP, Bekaii-Saab TS. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers. Chin Clin Oncol. 2023 Oct; 12(5):55.
    View PubMed
40. Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin Oncol. 2023 Sep 1; 41 (25):4097-4106 Epub 2023 Apr 26
    View PubMed
41. Eslinger C, Walden D, Barry T, Shah S, Samadder NJ, Bekaii-Saab TS. Rechallenge With Switching Immune Checkpoint Inhibitors Following Autoimmune Myocarditis in a Patient With Lynch Syndrome. J Natl Compr Canc Netw. 2023 Sep; 21 (9):894-899
    View PubMed
42. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
    View PubMed
43. Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers (Basel). 2023 Aug 15; 15 (16)
    View PubMed
44. Ou FS, Walden DJ, Larson JJ, Kang S, Griswold CR, Ueberroth BE, Patel B, Draper A, Raman P, Alese OB, Sonbol MB, Bekaii-Saab TS, Wu CS, Ahn DH. Changes in Prescribing Patterns in Stage III Colon Cancer. J Natl Compr Canc Netw. 2023 Aug; 21 (8):841-850.e4
    View PubMed
45. Strickler JH, Hsu LI, Wright P, Stecher M, Siadak MF, Palanca-Wessels MC, Yu J, Zhang N, Espenschied CR, Lang K, Bekaii-Saab TS. Real-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study. J Natl Compr Canc Netw. 2023 Aug; 21 (8):805-812.e1
    View PubMed
46. Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, McWilliams R, Ma WW, Bekaii-Saab TS, Stauffer J, Starr JS. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. JCO Precis Oncol. 2023 Aug; 7:e2200706
    View PubMed
47. Shaib WL, Manali R, Liu Y, El-Rayes B, Loehrer P, O'Neil B, Cohen S, Khair T, Robin E, Huyck T, Bekaii-Saab T. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Eur J Cancer. 2023 Aug; 189:112847 Epub 2023 Mar 11
    View PubMed
48. Bekaii-Saab TS. Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: colorectal cancer. Clin Adv Hematol Oncol. 2023 Jul; (7):355-357
    View PubMed
49. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023 Jun; 8 (3):101567 Epub 2023 May 31
    View PubMed
50. Serrano Uson Junior PL, Bekaii-Saab T. Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier? Immunotherapy. 2023 May; 15 (7):531-540 Epub 2023 Apr 25
    View PubMed
51. Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS, MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May; 24 (5):496-508
    View PubMed
52. McWilliams R, Rivera F, Evans J, Borad M, Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023 Apr 10; 41 (11):2007-2019 Epub 2022 Dec 15
    View PubMed
53. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 Apr; 7 (4):e2101319 Epub 2022 Mar 27
    View PubMed
54. Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, Esplin ED, Nussbaum RL, Heald B, Klint M, Barrus K, Uson PL Jr, Nguyen CC, Colon-Otero G, Bekaii-Saab TS, Dronca R, Kunze KL, Samadder NJ. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program. Cureus. 2023 Apr; 15 (4):e37428 Epub 2023 Apr 11
    View PubMed
55. Bekaii-Saab T, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, Fang W, Anderson EC, Noel MS, Reni M, Choi HJ, Goldberg JS, Oh SC, Li CP, Tabernero J, Li J, Foos E, Oh C, Van Cutsem E. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. EClinicalMedicine. 2023 Apr; 58:101897 Epub 2023 Mar 16
    View PubMed
56. Lam LL, Pavlakis N, Shitara K, Sjoquist KM, Martin AJ, Yip S, Kang YK, Bang YJ, Chen LT, Moehler M, Bekaii-Saab T, Alcindor T, O'Callaghan CJ, Tebbutt NC, Hague W, Chan H, Rha SY, Lee KW, Gebski V, Jaworski A, Zalcberg J, Price T, Simes J, Goldstein D. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer. 2023 Feb 22; 23 (1):180
    View PubMed
57. Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5; 388 (1):44-54 Epub 2022 Dec 21
    View PubMed
58. Grotz TE, Yonkus JA, Thiels CA, Warner SG, McWilliams RR, Mahipal A, Bekaii-Saab TS, Cleary SP, Kendrick ML, Truty MJ. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. Ann Surg Oncol. 2023 Jan; 30 (1):395-403 Epub 2022 Aug 16
    View PubMed
59. Sonbol MB, Siddiqi R, Uson PLS, Pathak S, Firwana B, Botrus G, Almader-Douglas D, Ahn DH, Borad MJ, Starr J, Jones J, Stucky CC, Smoot R, Riaz IB, Bekaii-Saab T. The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. Oncologist. 2022 Dec 9; 27 (12):1034-1040
    View PubMed
60. Cho SK, Bekaii-Saab T, Kavati A, Babajanyan S, Hocum B, Barzi A. Value-Based Analysis of Therapies in Refractory Metastatic Colorectal Cancer in US. Clin Colorectal Cancer. 2022 Dec; 21 (4):277-284 Epub 2022 Sept 17
    View PubMed
61. Hogenson TL, Xie H, Phillips WJ, Toruner MD, Li JJ, Horn IP, Kennedy DJ, Almada LL, Marks DL, Carr RM, Toruner M, Sigafoos AN, Koenig-Kappes AN, Olson RL, Tolosa EJ, Zhang C, Li H, Doles JD, Bleeker J, Barrett MT, Boyum JH, Kipp BR, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Petersen GM, Dasari S, Oberg AL, Truty MJ, Graham RP, Levy MJ, Zhu M, Billadeau DD, Adjei AA, Dusetti N, Iovanna JL, Bekaii-Saab TS, Ma WW, Fernandez-Zapico ME. Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight. 2022 Nov 22; 7 (22)
    View PubMed
62. Uson PLS Jr, Kunze KL, Golafshar MA, Botrus G, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Kahn A, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T, Samadder NJ. Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study. Dig Dis Sci. 2022 Nov; 67 (11):5107-5115 Epub 2022 Feb 05
    View PubMed
63. McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, Shroff R, Moehler M, Lowery M, Bekaii-Saab T, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature. BMJ Open. 2022 Oct 26; 12 (10):e064954
    View PubMed
64. Storandt MH, Gile JJ, Palmer ME, Zemla TJ, Ahn DH, Bekaii-Saab TS, Jin Z, Tran NH, Mahipal A. Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2022 Oct 22; 14 (21)
    View PubMed
65. Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022 Oct 1; 27 (10):874-883
    View PubMed
66. Ahn DH, Bekaii-Saab T. The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer. JAMA Oncol 2022 Sep 1; 8 (9):1257-1259
    View PubMed
67. Ueberroth BE, Jones JC, Bekaii-Saab TS. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology. 2022 Sep; 22 (6):741-748 Epub 2022 June 12
    View PubMed
68. Gile JJ, Wookey V, Zemla TJ, Shi Q, Jin Z, Alberts SR, McWilliams RR, Ma WW, Borad M, Bekaii-Saab TS, Tran NH, Mahipal A. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. Target Oncol. 2022 Sep; 17 (5):529-538 Epub 2022 Sept 02
    View PubMed
69. Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. J Clin Oncol. 2022 Aug 20; 40 (24):2706-2715 Epub 2022 June 01
    View PubMed
70. Uson Junior PLS, DeLeon TT, Bogenberger JM, Pai RK, Kosiorek HE, Yin J, Ahn DH, Sonbol MB, Bekaii-Saab T, Mansfield AS, Buetow K, Gores GJ, Smoot R, Vasmatzis G, Kipp BR, Mahipal A, Baker AT, Babiker H, Barro O, Dumbauld C, Zhou Y, Aslam FN, Barrett M, Jacobs B, Meurice N, Arora M, Petit J, Elliott N, Nagalo B, Salomao MA, Borad MJ. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Dig Dis Sci. 2022 Aug; 67(8):3797-3805. Epub 2021 Nov 13.
    View PubMed
71. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clin Cancer Res. 2022 Jul 15; 28 (14):3021-3031
    View PubMed
72. Ueberroth BE, Jones JC, Bekaii-Saab T. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies. Clin Adv Hematol Oncol. 2022 Jul; 20 (7):444-455
    View PubMed
73. Zhu M, Bekaii-Saab T. Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors". Oncologist 2022 Jun 8; 27 (6):e534-e535
    View PubMed
74. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
75. Strickler JH, Yoshino T, Graham RP, Siena S, Bekaii-Saab T. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. JAMA Oncol. 2022 May 1; 8 (5):760-769
    View PubMed
76. Ahn D, Walden D, Bekaii-Saab T. Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert Opin Investig Drugs. 2022 May; 31 (5):437-441 Epub 2022 Mar 17
    View PubMed
77. Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 Apr 5; 27 (4):292-298
    View PubMed
78. Zhu M, Bekaii-Saab TS. Acquired Immunotherapy Resistance in Gastrointestinal Cancers. JAMA Netw Open 2022 Mar 1; 5 (3):e224646 Epub 2022 Mar 01
    View PubMed
79. Sonbol MB, Pathak S, Bekaii-Saab T. The treatment landscape for gastroesophageal adenocarcinomas. Clin Adv Hematol Oncol. 2022 Mar; 20 (3):169-177
    View PubMed
80. Uson Junior PL, Kunze KL, Golafshar MA, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Barrus K, Mountjoy L, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T, Samadder NJ. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. Cancer Prev Res (Phila). 2022 Feb; 15 (2):121-128 Epub 2021 Nov 15
    View PubMed
81. Laughlin BS, Petersen MM, Yu NY, Anderson JD, Rule WG, Borad MJ, Aqel BA, Sonbol MB, Mathur AK, Moss AA, Bekaii-Saab TS, Ahn DH, DeWees TA, Sio TT, Ashman JB. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. J Gastrointest Oncol. 2022 Feb; 13 (1):288-297
    View PubMed
82. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1; 5 (2):e2149040 Epub 2022 Feb 01
    View PubMed
83. Ahn DH, Uson Junior PLS, Masci P, Kosiorek H, Halfdanarson TR, Mody K, Babiker H, DeLeon T, Sonbol MB, Gores G, Smoot R, Bekaii-Saab T, Mahipal A, Mansfield A, Tran NH, Hubbard JM, Borad MJ. A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Invest New Drugs. 2022 Feb; 40 (1):134-141 Epub 2021 Aug 31
    View PubMed
84. Wintheiser G, Zemla T, Shi Q, Tran N, Prasai K, Tella SH, Mody K, Ahn D, Borad M, Bekaii-Saab T, Mahipal A. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precis Oncol. 2022 Jan; 6:e2100156
    View PubMed
85. Akce M, El-Rayes BF, Bekaii-Saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol. 2022; 15:17562848221086126 Epub 2022 Apr 11
    View PubMed
86. Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, Chen X, Serrano Uson Junior PL, Dumbauld CR, Baker AT, Gamb SI, Egan JB, Zhou Y, Nagalo BM, Meurice N, Eskelinen EL, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Buetow KH, Sonbol MB, Mansfield AS, Roberts LR, Bekaii-Saab TS, Ahn DH, Truty MJ, Borad MJ. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology. 2022 Jan; 75 (1):43-58 Epub 2021 Dec 12
    View PubMed
87. McNamara MG, Bridgewater J, Goyal L, Jacobs T, Wagner AD, Goldstein D, Shroff R, Moehler M, Lowery M, Bekaii-Saab T, Kelley RK, Furuse J, Rimassa L, Morizane C, Lamarca A, Hubner R, Knox J, Valle J. What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature. BMJ Open. 2022; 12 (10):e064954
    
88. Walden D, Eslinger C, Bekaii-Saab T. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements. Therap Adv Gastroenterol. 2022; 15:17562848221115317 Epub 2022 Aug 06
    View PubMed
89. Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics Syst Pharmacol. 2021 Dec; 10 (12):1550-1563 Epub 2021 Nov 20
    View PubMed
90. Tran NH, Bekaii-Saab T. Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. JAMA Netw Open 2021 Nov 1; 4 (11):e2134458 Epub 2021 Nov 01
    View PubMed
91. Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother. 2021 Nov; 70 (11):3337-3348 Epub 2021 June 23
    View PubMed
92. Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park). 2021 Oct 21; 35 (10):654-660
    View PubMed
93. Uson PLS Jr, Samadder NJ, Riegert-Johnson D, Boardman L, Borad MJ, Ahn D, Sonbol MB, Faigel DO, Fukami N, Pannala R, Kunze K, Golafshar M, Klint M, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab T. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Clin Transl Gastroenterol. 2021 Oct 8; 12 (10):e00414 Epub 2021 Oct 08
    View PubMed
94. Bekaii-Saab TS, Raghav K, Wainberg ZA. How quality of life can inform management decisions in later-line metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22 (10):1-16
    View PubMed
95. Bekaii-Saab TS. Recent quality-of-life data in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22 (10):6-10
    View PubMed
96. Bekaii-Saab TS, Raghav K, Wainberg ZA. How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A. Clin Adv Hematol Oncol. 2021 Oct; 19 Suppl 22 (10):13-14
    View PubMed
97. Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 Oct; 6 (10):803-815 Epub 2021 Aug 03
    View PubMed
98. Ciombor K, Jones J, Strickler J, Bekaii-Saab T, Wu C. The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. Oncology (Williston Park). 2021 Sep 15; 35 (9):553-559 Epub 2021 Sept 15
    View PubMed
99. Bekaii-Saab TS. Highlights in colorectal cancer from the 2021 American Society of Clinical Oncology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2021 Sep; 19 Suppl 21 (9):11-15
    View PubMed
100. Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol. 2021 Sep 1; 39 (25):2803-2815 Epub 2021 June 02
     View PubMed
101. Afifi AM, Elmehrath AO, Ruhban IA, Saad AM, Gad MM, Al-Husseini MJ, Bekaii-Saab T, Sonbol MB. Causes of Death Following Nonmetastatic Colorectal Cancer Diagnosis in the U.S.: A Population-Based Analysis. Oncologist. 2021 Sep; 26 (9):733-739 Epub 2021 June 30
     View PubMed
102. Li JJ, Zhu M, Kashyap PC, Chia N, Tran NH, McWilliams RR, Bekaii-Saab TS, Ma WW. The role of microbiome in pancreatic cancer. Cancer Metastasis Rev. 2021 Sep; 40 (3):777-789 Epub 2021 Aug 28
     View PubMed
103. Bekaii-Saab TS. Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation. Clin Adv Hematol Oncol. 2021 Aug; 19 Suppl 20 (8):1-8
     View PubMed
104. Sahin IH, Goyal S, Pumpalova Y, Sonbol MB, Das S, Haraldsdottir S, Ahn D, Ciombor KK, Chen Z, Draper A, Berlin J, Bekaii-Saab T, Lesinski GB, El-Rayes BF, Wu C. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. Oncologist. 2021 Aug; 26 (8):668-675 Epub 2021 Mar 22
     View PubMed
105. Ueberroth BE, Liu AJ, Graham RP, Bekaii-Saab TS, McWilliams RR, Mahipal A, Truty MJ, Mody K, Sonbol MB, Halfdanarson TR. Osteoclast-Like Giant Cell Tumors of the Pancreas: Clinical Characteristics, Genetic Testing, and Treatment Modalities. Pancreas. 2021 Aug 1; 50 (7):952-956
     View PubMed
106. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 Jul; 26 (7):610-618 Epub 2021 Mar 06
     View PubMed
107. Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, Bekaii-Saab T, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res. 2021 Jul 1; 27 (13):3641-3648 Epub 2021 Apr 21
     View PubMed
108. Wainberg ZA, Bekaii-Saab T, Boland PM, Dayyani F, Macarulla T, Mody K, Belanger B, Maxwell F, Moore Y, Thiagalingam A, Wang T, Zhang B, Dean A. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Eur J Cancer. 2021 Jul; 151:14-24 Epub 2021 May 04
     View PubMed
109. Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Oncologist. 2021 Jul; 26 (7):569-578 Epub 2021 Mar 05
     View PubMed
110. Sonbol MB, Riaz IB, Bekaii-Saab T. Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data-Reply. JAMA Oncol 2021 Jun 1; 7 (6):941
     View PubMed
111. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 Jun; 32 (6):787-800 Epub 2021 Mar 19
     View PubMed
112. Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, Bekaii-Saab TS, Halfdanarson TR, Sonbol MB. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. Clin Colorectal Cancer. 2021 Jun; 20 (2):e139-e149 Epub 2020 Dec 17
     View PubMed
113. Uson Junior PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? Semin Liver Dis. 2021 May; 41 (2):136-141 Epub 2021 May 06
     View PubMed
114. Sipra QUAR, Islam M, Riaz IB, Zhaohui J, Babiker HM, Bekaii-Saab TS, Sonbol MB. Contemporary Management of Pancreatic Cancer from an Internist Perspective. Am J Med. 2021 May; 134 (5):576-586 Epub 2020 Dec 11
     View PubMed
115. Botrus G, Raman P, Oliver T, Bekaii-Saab T. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr; 30 (4):309-316 Epub 2021 Jan 04
     View PubMed
116. Smith CJ, Bekaii-Saab TS, Cook KD, Eiring RA, Halfdanarson TR, Hanna M, Jin Z, Jochum JA, Ma WW, Mitchell JL, Pitot HC, Jatoi A. Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. Pancreatology. 2021 Mar; 21 (2):379-383 Epub 2020 Oct 18
     View PubMed
117. Lawal B, Lin LC, Lee JC, Chen JH, Bekaii-Saab TS, Wu ATH, Ho CL. Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. Cancers (Basel). 2021 Feb 25; 13 (5)
     View PubMed
118. Uson Junior PLS, Liu AJ, Sonbol MB, Borad MJ, Bekaii-Saab TS. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. Chin Clin Oncol. 2021 Feb; 10 (1):11
     View PubMed
119. Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, Bekaii-Saab TS, Sekulic A, Stewart AK. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021 Feb 1; 7 (2):230-237
     View PubMed
120. Botrus G, Uson Junior PLS, Raman P, Kaufman AE, Kosiorek H, Yin J, Fu Y, Majeed U, Sonbol MB, Ahn DH, Chang IW, Drusbosky LM, Dada H, Starr J, Borad M, Mody K, Bekaii-Saab TS. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Front Oncol. 2021; 11:794009 Epub 2022 Jan 10
     View PubMed
121. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
     View PubMed
122. Walden D, Sonbol MB, Buckner Petty S, Yoon HH, Borad M, Bekaii-Saab TS, Ahn DH. Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. Front Oncol. 2021; 11:641044 Epub 2021 Sept 10
     View PubMed
123. Marshall JL, Loupakis F, Bekaii-Saab TS. Transitioning from second-line to third-line therapy in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 3 (1):1-20
     View PubMed
124. Bekaii-Saab TS. Proactive transitioning to third-line treatment in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 3 (1):5-7
     View PubMed
125. Marshall JL, Bekaii-Saab TS, Loupakis F. Q&A: colorectal cancer in younger patients. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 3 (1):15-17
     View PubMed
126. Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. J Pancreat Cancer. 2021; 7 (1):8-19 Epub 2021 Mar 23
     View PubMed
127. Chen LT, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology. 2021 Jan; 21 (1):192-199 Epub 2020 Oct 10
     View PubMed
128. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 Dec 16; 10 (1):22087
     View PubMed
129. Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020 Dec 1; 6 (12):e204930 Epub 2020 Dec 10
     View PubMed
130. McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, Andre T, Cunningham D, Moehler M, Jensen LH, Koeberle D, Bekaii-Saab T, Bridgewater J, Valle JW. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. J Hepatol. 2020 Nov; 73 (5):1109-1117 Epub 2020 May 21
     View PubMed
131. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov; 25 (11):e1681-e1690 Epub 2020 Aug 04
     View PubMed
132. Bekaii-Saab TS. Cases in the management of metastatic colorectal cancer: sequencing therapies in a patient with the BRAF V600E mutation. Clin Adv Hematol Oncol. 2020 Nov; 18 Suppl 19 (11):1-8
     View PubMed
133. Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater J, Wasan H, Borad MJ, Abou-Alfa GK, Jiang P, Lihou CF, Zhen H, Asatiani E, Feliz L, Vogel A. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020 Oct; 16 (30):2385-2399 Epub 2020 July 17
     View PubMed
134. Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology. 2020 Oct 1; 9 (1):1818437 Epub 2020 Oct 01
     View PubMed
135. Sykora D, Landman N, Butterfield RJ, Bekaii-Saab TS, Chang YH, Cortese DA. Predictive factors of improved postoperative outcomes in pancreatic resection include patient insurance status and facility surgical volume Annals of Pancreatic Cancer. 2020; 3(12).
     
136. Ware MB, Zaidi MY, Yang J, Turgeon MK, Krasinskas A, Mace TA, Keenan K, Farren MR, Ruggieri AN, Li Y, Zhang C, Chen Z, Young GS, Elnaggar O, Che Z, Maithel SK, Bekaii-Saab T, El-Rayes B, Lesinski GB. Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. Br J Cancer. 2020 Oct; 123 (9):1377-1386 Epub 2020 Aug 04
     View PubMed
137. Morris VK, Bekaii-Saab T. Improvements in Clinical Outcomes for BRAF(V600E) -Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Sep 1; 26 (17):4435-4441 Epub 2020 Apr 06
     View PubMed
138. Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, Johnson GB, Allred JB, Yin J, Lim VS, Bekaii-Saab T, Ma WW, Erlichman C, Adjei AA, Fernandez-Zapico ME. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology. 2020 Sep; 20 (6):1115-1122 Epub 2020 July 14
     View PubMed
139. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug; 43 (8):586-590
     View PubMed
140. Zhu M, Sonbol MB, Bassam Sonbol M, Halfdanarson T, Hobday T, Ahn D, Ma WW, Bekaii-Saab T. Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Oncologist. 2020 Aug; 25 (8):e1246-e1248 Epub 2020 July 01
     View PubMed
141. Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 Jul 1; 26 (13):3117-3125 Epub 2020 Apr 06
     View PubMed
142. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20; 395 (10241):1907-1918 Epub 2020 May 28
     View PubMed
143. O'Reilly EM, Barone D, Mahalingam D, Bekaii-Saab T, Shao SH, Wolf J, Rosano M, Krause S, Richards DA, Yu KH, Roach JM, Flaherty KT, Ryan DP. Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. Eur J Cancer. 2020 Jun; 132:112-121 Epub 2020 Apr 28
     View PubMed
144. Sonbol MB, Murad MH, Bekaii-Saab T. The Role of Maintenance Therapy in Metastatic Colorectal Cancer-Reply. JAMA Oncol 2020 Jun 1; 6 (6):937-938
     View PubMed
145. Almquist DR, Ahn DH, Bekaii-Saab TS. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. BioDrugs. 2020 Jun; 34 (3):349-362
     View PubMed
146. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
     View PubMed
147. Li Y, Zhang HB, Chen X, Yang X, Ye Y, Bekaii-Saab T, Zheng Y, Zhang Y. A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. Oncologist. 2020 Mar; 25 (3):203-207 Epub 2019 Oct 22
     View PubMed
148. Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020 Mar 1; 6 (3):e194489 Epub 2020 Mar 12
     View PubMed
149. Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen CS, Coss CC. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. EMBO Mol Med. 2020 Feb 7; 12 (2):e9910 Epub 2020 Jan 13
     View PubMed
150. Ahn DH, Bekaii-Saab T. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. Chin Clin Oncol. 2020 Feb; 9 (1):6 Epub 2020 Feb 20
     View PubMed
151. Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 2020 Feb; 49 (2):193-200
     View PubMed
152. McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020 Jan; 20 (1):101-109 Epub 2019 Nov 21
     View PubMed
153. Loupakis F, Antonuzzo L, Bachet JB, Kuan FC, Macarulla T, Pietrantonio F, Xu RH, Taniguchi H, Winder T, Yuki S, Zeng S, Bekaii-Saab T. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther Adv Med Oncol. 2020; 12:1758835920956862 Epub 2020 Oct 31
     View PubMed
154. Grothey A, Bekaii-Saab TS, Yoshino T, Prager GW. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol. 2020 Jan; 18 Suppl 2 (1):1-24
     View PubMed
155. Bekaii-Saab TS. Identifying disease progression in patients with metastatic colorectal cancer: when to initiate third-line therapy. Clin Adv Hematol Oncol. 2020 Jan; 18 Suppl 2 (1):2-7
     View PubMed
156. Grothey A, Prager GW, Yoshino T, Bekaii-Saab TS. Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancer: discussion. Clin Adv Hematol Oncol. 2020 Jan; 18 Suppl 2 (1):21-23
     View PubMed
157. Bekaii-Saab T. Navigating an increasingly complex treatment landscape in the management of hepatocellular carcinoma (HCC). Journal of Managed Care Medicine. 2020; 23 (3):36-9
     
158. Yang M, Hopp AC, Bekaii-Saab TS, Collins JM. Sister Mary Joseph Nodule in Advanced Pancreatic Adenocarcinoma Identified on (18)F-FDG PET/MRI. J Nucl Med Technol. 2019 Dec; 47 (4):341-342 Epub 2019 Apr 24
     View PubMed
159. Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. JCO Precis Oncol. 2019 Dec; 3:1-9
     View PubMed
160. Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, Tan BR Jr, Kavan P, Goel R, Lammers PE, Bekaii-Saab TS, Tam VC, Rajdev L, Kelley RK, El Dika I, Zemla T, Potaracke RI, Balletti J, El-Khoueiry AB, Harding JJ, Suga JM, Schwartz LH, Goldberg RM, Bertagnolli MM, Meyerhardt J, O'Reilly EM, Venook AP. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019 Nov 1; 5 (11):1582-1588
     View PubMed
161. Li Y, Zhang HB, Chen X, Yang X, Ye Y, Bekaii-Saab T, Zheng Y, Zhang Y. A Rare EGFR-SEPT14 Fusion in a Patient with Colorectal Adenocarcinoma Responding to Erlotinib. Oncologist. 2019 Oct 22 [Epub ahead of print]
     View PubMed
162. Chen M, Cao J, Bai Y, Tong C, Lin J, Jindal V, Barchi LC, Nadalin S, Yang SX, Pesce A, Panaro F, Ariche A, Kai K, Memeo R, Bekaii-Saab T, Cai X, Written on behalf of the AME Gallbladder Cancer Collaborative Group. Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions. Clin Transl Gastroenterol. 2019 Oct; 10 (10):e00098
     View PubMed
163. Ahn DH, Bekaii-Saab T. AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time? Chin Clin Oncol 2019 Oct; 8 (S1):S19 Epub 2019 May 06
     View PubMed
164. Sonbol MB, Benkhadra R, Wang Z, Firwana B, Walden DJ, Mody K, Hubbard JM, Murad MH, Ahn DH, Bekaii-Saab T. A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer. Oncologist. 2019 Sep; 24 (9):1174-1179 Epub 2019 June 04
     View PubMed
165. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug; 20 (8):1070-1082 Epub 2019 June 28
     View PubMed
166. Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Cancers (Basel). 2019 Jul 28; 11 (8) Epub 2019 July 28
     View PubMed
167. Reni M, Riess H, O'Reilly E, Santoro A, Park J, Bekaii-Saab T, Tempero M, Shan Y, Macarulla T, Van Cutsem E, Noel M, Berlin J, Biankin A, Dhani N, Frassineti G, Goldstein D, Romano A, Bruchec YL, Philip P. An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Ann Oncol. 2019 Jul; 30 Suppl 4:iv126 Epub 2019 Dec 04
     View PubMed
168. Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 15; 25(12):3495-3507. Epub 2019 Feb 25.
     View PubMed
169. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1; 5 (6):824-830
     View PubMed
170. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019 May 14 [Epub ahead of print]
     View PubMed
171. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Apr 20; 37 (12):1015-1027 Epub 2019 Mar 11
     View PubMed
172. Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Apr 15; 25 (8):2403-2413 Epub 2018 Nov 13
     View PubMed
173. Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T. CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. Future Oncol. 2019 Apr; 15 (12):1295-1302 Epub 2019 Feb 15
     View PubMed
174. Mody K, Kasi PM, Yang JD, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A, Nagy R, Lanman R, Borad MJ. Circulating tumor dna profiling of advanced biliary tract cancers JCO Precision Oncology. 2019 Mar 18; 3
     
175. Sonbol MB, Ahn DH, Bekaii-Saab T. Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. Biomedicines. 2019 Mar 10; 7 (1)
     View PubMed
176. Ahn DH, Bekaii-Saab T. Watch and Wait in Rectal Cancer: Who's In and Who's Out? J Oncol Pract 2019 Mar; 15 (3):133-134
     View PubMed
177. Bekaii-Saab T, Kim R, Kim TW, O'Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer. 2019 Mar; 18 (1):e117-e129 Epub 2018 Nov 16
     View PubMed
178. Grothey A, Marshall JL, Bekaii-Saab T. Sequencing beyond the second-line setting in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2019 Mar; 17 Suppl 7 (3):1-19
     View PubMed
179. Bekaii-Saab T. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer. Clin Adv Hematol Oncol. 2019 Mar; 17 Suppl 7 (3):5-13
     View PubMed
180. Grothey A, Marshall JL, Bekaii-Saab T. Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations. Clin Adv Hematol Oncol. 2019 Mar; 17 Suppl 7 (3):16-18
     View PubMed
181. Wang CB, Shahjehan F, Merchea A, Li Z, Bekaii-Saab TS, Grothey A, Colibaseanu DT, Kasi PM. Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study. Front Oncol. 2019; 9:76 Epub 2019 Feb 19
     View PubMed
182. Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 2019 Jan; 19 (1):80-87 Epub 2018 Nov 10
     View PubMed
183. Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol. 2018 Dec; 9 (6):1063-1073
     View PubMed
184. Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 Dec; 36 (6):1037-1043 Epub 2018 May 22
     View PubMed
185. Chu PC, Kulp SK, Bekaii-Saab T, Chen CS. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Small GTPases. 2018 Nov 2; 9 (6):452-456 Epub 2016 Dec 09
     View PubMed
186. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12
     View PubMed
187. Bekaii-Saab T. A closer look at regorafenib. Clin Adv Hematol Oncol. 2018 Oct; 16 (10):667-669
     View PubMed
188. Pant S, Hubbard J, Martinelli E, Bekaii-Saab T. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Crit Rev Oncol Hematol. 2018 Oct; 130:78-91 Epub 2018 Aug 02
     View PubMed
189. Chen LT, Macarulla TM, Blanc J, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke J. Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. Ann Oncol. 2018 Oct; 29 Suppl 8:viii250-viii251
     View PubMed
190. Ahn D, Barzi A, Miksad RA, Surinach A, Corvino FA, Valderrama A, Mamlouk K, Pulgar S, Bekaii-Saab T. Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics. Ann Oncol. 2018 Oct; 29 Suppl 8:viii251
     View PubMed
191. Javle M, Kelley RK, Roychowdhury S, Weiss KH, Abou-Alfa GK, Macarulla T, Sadeghi S, Waldschmidt D, Zhu AX, Goyal L, Borad M, Yong WP, Borbath I, El-Khoueiry A, Philip P, Moran S, Ye Y, Ising M, Lewis N, Bekaii-Saab T. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann Oncol. 2018 Oct; 29 Suppl 8:viii720
     View PubMed
192. Bekaii-Saab T, Yu K, Lima CMSR, Wolin EM. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma. Clin Adv Hematol Oncol. 2018 Sep; 16 Suppl 17 (9):1-16
     View PubMed
193. Bekaii-Saab T. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma. Clin Adv Hematol Oncol. 2018 Sep; 16 Suppl 17 (9):5-7
     View PubMed
194. Bekaii-Saab T. New guideline-sanctioned and emerging interventions for pancreatic cancer. Clin Adv Hematol Oncol. 2018 Sep; 16 Suppl 17 (9):7-9
     View PubMed
195. Bekaii-Saab T. How I treat metastatic colorectal cancer. Clin Adv Hematol Oncol 2018 Sep; 16 Suppl 18 (9):2-6
     View PubMed
196. DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ. Novel immunotherapy strategies for hepatobiliary cancers. Immunotherapy. 2018 Sep; 10 (12):1077-1091
     View PubMed
197. Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. Cancer. 2018 Aug 1; 124 (15):3118-3126 Epub 2018 June 15
     View PubMed
198. Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer. Cancer J. 2018 Jul/Aug; 24 (4):165-170
     View PubMed
199. Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel). 2018 Jun 11; 10 (6) Epub 2018 June 11
     View PubMed
200. Chu PC, Lin PC, Wu HY, Lin KT, Wu C, Bekaii-Saab T, Lin YJ, Lee CT, Lee JC, Chen CS. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. Oncogene. 2018 Jun; 37 (25):3440-3455 Epub 2018 Mar 21
     View PubMed
201. Herrmann T, Carothers A, Littman G, Warters M, Cason C, Bekaii-Saab T. Management of patients with unresectable HCC: A simulation-based assessment of medical oncologists' practice choices. Ann Oncol. 2018 Jun; 29 Suppl 5:v48 Epub 2020 Jan 07
     View PubMed
202. Bekaii-Saab T, Okusaka T, Goldstein D, O'Neill B, Tabernero J, Li C, Reni M, Jin B, Oh C, Borodyansky L, Van Cutsem E. CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress. Ann Oncol. 2018 Jun; 29 Suppl 5:v51-v52 Epub 2020 Jan 07
     View PubMed
203. Bekaii-Saab T, Marcello K, Fisher G, Kopetz S, Strickler J, Venook A, Obholz K. Variability of current global practice patterns in the management of metastatic colorectal cancer. Ann Oncol. 2018 Jun; 29 Suppl 5:v73 Epub 2020 Jan 07
     View PubMed
204. Herrmann T, Cameron D, Carothers A, Bekaii-Saab T. Integrating a paradigm shift in the treatment of metastatic colorectal cancer: Effect of online CME on oncologists' knowledge and competence. Ann Oncol. 2018 Jun; 29 Suppl 5:v81 Epub 2020 Jan 07
     View PubMed
205. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105 Epub 2020 Jan 07
     View PubMed
206. Ahn DH, Reardon J, Ahn CW, Bupathi M, Mikhail S, Wu CS, Bekaii-Saab T. Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer. Int J Cancer. 2018 Apr 15; 142 (8):1671-1675 Epub 2017 Nov 17
     View PubMed
207. Sonbol MB, Bekaii-Saab T. A clinical trial protocol paper discussing the BRIGHTER study. Future Oncol. 2018 Apr; 14 (10):901-906 Epub 2018 Jan 03
     View PubMed
208. Mody K, Bekaii-Saab T. Clinical Trials and Progress in Metastatic Colon Cancer. Surg Oncol Clin N Am. 2018 Apr; 27 (2):349-365
     View PubMed
209. Ahn DH, Bekaii-Saab TS. Genetic Diversity and Treatment Implications in Gastric and Gastroesophageal Cancers: One Size Does Not Fit All. J Oncol Pract 2018 Apr; 14 (4):227-228
     View PubMed
210. DeLeon TT, Ahn DH, Bogenberger JM, Anastasiadis PZ, Arora M, Ramanathan RK, Aqel BA, Vasmatzis G, Truty MJ, Oklu R, Bekaii-Saab TS, Borad MJ. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncol. 2018 Mar; 14 (6):553-566 Epub 2018 Feb 20
     View PubMed
211. Bekaii-Saab T. Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. Clin Adv Hematol Oncol. 2018 Mar; 16 Suppl 7 (3):16-18
     View PubMed
212. Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, Zhong X, Zimmers TA, Ostrowski MC, Ludwig T, Bloomston M, Bekaii-Saab T, Lesinski GB. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018 Feb; 67 (2):320-332 Epub 2016 Oct 21
     View PubMed
213. Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, Bekaii-Saab T, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol. 2018 Feb; 41(2):140-146.
     View PubMed
214. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 Jan 20; 36 (3):276-282 Epub 2017 Nov 28
     View PubMed
215. Ciombor KK, Bekaii-Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist. 2018 Jan; 23 (1):25-34 Epub 2017 Oct 11
     View PubMed
216. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma with FGFR genetic aberrations: A unique clinical phenotype JCO Precision Oncology. 2018; 2
     
217. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol. 2017 Dec; 40(6):531-534.
     View PubMed
218. Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, Bekaii-Saab T, Chakravarti A, Wuthrick E, Williams TM. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. Am J Clin Oncol. 2017 Dec; 40(6):561-568.
     View PubMed
219. Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 2017 Dec 1; 123 (23):4680-4686 Epub 2017 Aug 17
     View PubMed
220. Strickler JH, Wu C, Bekaii-Saab T. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. Cancer Treat Rev. 2017 Nov; 60:109-119 Epub 2017 Aug 31
     View PubMed
221. Bekaii-Saab T. Advances in the management of pancreatic adenocarcinoma: guidelines and clinical practice Clinical Advances In Hematology & Oncology. 2017 Nov; 15 (11 Suppl 12):11-4
     
222. Nemer L, Krishna SG, Shah ZK, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Guttridge DC, Hinton A, Manilchuk A, Pawlik TM, Schmidt CR, Talbert EE, Bekaii-Saab T, Hart PA. Predictors of Pancreatic Cancer-Associated Weight Loss and Nutritional Interventions. Pancreas. 2017 Oct; 46 (9):1152-1157
     View PubMed
223. Pershad Y, Govindan S, Hara AK, Borad MJ, Bekaii-Saab T, Wallace A, Albadawi H, Oklu R. Using Naive Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. Diagnostics (Basel). 2017 Sep 2; 7 (3) Epub 2017 Sept 02
     View PubMed
224. Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF. Appendiceal Mucinous Neoplasms: Diagnosis and Management. Oncologist. 2017 Sep; 22 (9):1107-1116 Epub 2017 June 29
     View PubMed
225. Ahn DH, Bekaii-Saab T. Response to Drs Von Hoff and Renschler. Ther Adv Med Oncol. 2017 Jun; 9 (6):445-446 Epub 2017 May 30
     View PubMed
226. Bekaii-Saab T, Starodub A, El-Rayes B, O'Neil B, Shahda S, Ciombor K, Noonan A, Hanna W, Sehdev A, Shaib W, Mikhail S, Neki A, Oh C, Li YZ, Li W, Borodyansky L, Li CJ. A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts). Ann Oncol. 2017 Jun; 28 Suppl 3:iii150
     View PubMed
227. Bekaii-Saab T, Goldstein D, Li CP, Okusaka T, O'Neil B, Reni M, Tabernero J, Qin S, Van Cutsem E, Borodyansky L, Li CJ, other CanStem111P Investigators. CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). Ann Oncol. 2017 Jun; 28 Suppl 3:iii136
     View PubMed
228. Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N, Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren MR, Mace TA, Schmidt C, Liu Y, Deng D, Hwang RF, Zhou L, Moore T, Chatterjee D, Wang H, Leng X, Arlinghaus RB, Logsdon CD, Cruz-Monserrate Z. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Cancer Res. 2017 May 15; 77 (10):2647-2660 Epub 2017 Mar 01
     View PubMed
229. Kabir, Bekaii-Saab Tanios. Optimizing Sequencing Beyond Disease Progression After Second-Line Therapy in Metastatic Colorectal Cancer American Journal of Hematology/Oncology.2017;
     
230. Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, Bekaii-Saab T, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun. 2017 May 3; 8:14755 Epub 2017 May 03
     View PubMed
231. Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opin Ther Targets. 2017 May; 21 (5):485-498 Epub 2017 Mar 17
     View PubMed
232. Bekaii-Saab T, El-Rayes B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer. 2017 Apr 15; 123 (8):1303-1312 Epub 2017 Jan 24
     View PubMed
233. McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW. Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer. 2017 Apr 12; 17 (1):262
     View PubMed
234. Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017 Apr; 8 (2):293-301
     View PubMed
235. Bupathi M, Ahn DH, Bekaii-Saab T. Therapeutic options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017 Apr; 6 (2):91-100
     View PubMed
236. Ahn DH, Bekaii-Saab T. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies. Biomedicines. 2017 Mar 4; 5 (1) Epub 2017 Mar 04
     View PubMed
237. Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28; 116 (5):575-583 Epub 2017 Feb 02
     View PubMed
238. Talbert EE, Yang J, Mace TA, Farren MR, Farris AB, Young GS, Elnaggar O, Che Z, Timmers CD, Rajasekera P, Maskarinec JM, Bloomston M, Bekaii-Saab T, Guttridge DC, Lesinski GB. Dual Inhibition of MEK and PI3KAkt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 Feb; 16: (2)344-356.
     View PubMed
239. Mikhail S, Wei L, Salem ME, Bekaii-Saab T. Outcomes of definitive chemoradiation in patients with esophageal cancer. Dis Esophagus. 2017 Feb 1; 30 (2):1-7
     View PubMed
240. Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol. 2017 Feb; 9 (2):75-82 Epub 2016 Nov 02
     View PubMed
241. Bekaii-Saab T, Goel S, Dickerson A, Von Roenn J, Thompson MA, Tsao AS. Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. J Oncol Pract. 2017 Jan; 13 (1):e62-e67 Epub 2016 Nov 22
     View PubMed
242. Ramanathan RK, Bekaii-Saab T. Recent advances in the treatment of pancreatic adenocarcinoma: Further observations Clinical Advances in Hematology and Oncology. 2017; 15 (11):15
     
243. Braiteh F, Ramanathan RK, Bekaii-Saab T. Recent advances in the treatment of pancreatic adenocarcinoma Clinical Advances in Hematology and Oncology. 2017; 15 (11):1-2
     
244. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122 (24):3838-3847 Epub 2016 Sept 13
     View PubMed
245. Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 Dec 1; 122 (23):3657-3666 Epub 2016 Aug 06
     View PubMed
246. Abdel-Misih SR, Wei L, Benson AB 3rd, Cohen S, Lai L, Skibber J, Wilkinson N, Weiser M, Schrag D, Bekaii-Saab T. Neoadjuvant Therapy for Rectal Cancer Affects Lymph Node Yield and Status Without Clear Implications on Outcome: The Case for Eliminating a Metric and Using Preoperative Staging to Guide Therapy. J Natl Compr Canc Netw. 2016 Dec; 14 (12):1528-1534
     View PubMed
247. Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia. 2016 Dec; 18 (12):765-774 Epub 2016 Nov 25
     View PubMed
248. Turner JL, Reardon J, Bekaii-Saab T, Cataland SR, Arango MJ. Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. Clin Colorectal Cancer. 2016 Sep 20 Epub 2016 Sept 20
     View PubMed
249. Haraldsdottir S, Hampel H, Wu C, Weng DY, Shields PG, Frankel WL, Pan X, de la Chapelle A, Goldberg RM, Bekaii-Saab T. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet Med. 2016 Sep; 18(9):863-8. Epub 2016 Feb 11.
     View PubMed
250. Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, Truty M, Kindler H, Lowy AM, Bekaii-Saab T, Philip P, Talamonti M, Cardin D, LoConte N, Shen P, Hoffman JP, Venook AP. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 Aug 17; 151 (8):e161137
     View PubMed
251. Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol. 2016 Jul 7; 22 (25):5668-77
     View PubMed
252. Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst. 2016 Jul; 108: (7).
     View PubMed
253. Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, Hays J, Wu C, Abdel-Misih S. Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. Ann Surg Oncol. 2016 Jul; 23(7):2281-6. Epub 2016 Mar 10.
     View PubMed
254. Vargo CA, Blazer M, Reardon J, Gulati M, Bekaii-Saab T. Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm. Clin Colorectal Cancer. 2016 Jun; 15: (2)e61-3.
     View PubMed
255. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24 (6):1150-1158 Epub 2016 Apr 04
     View PubMed
256. Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15; 22(10):2565-74. Epub 2015 Dec 30.
     View PubMed
257. Mikhail S, Faltas B, Salem ME, Bekaii-Saab T. Application of next-generation sequencing in gastrointestinal and liver tumors. Cancer Lett. 2016 May 1; 374: (2)187-91.
     View PubMed
258. Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Med Oncol. 2016 May; 33: (5)48.
     View PubMed
259. Shaib W, Krishna K, Kim S, Goodman M, Rock J, Chen Z, Brutcher E, Staley CI, Maithel SK, Abdel-Missih S, El-Rayes BF, Bekaii-Saab T. Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. Cancer Res Treat. 2016 Apr; 48: (2)596-604.
     View PubMed
260. Bupathi M, Ahn DH, Wu C, Ciombor KK, Stephens JA, Reardon J, Goldstein DA, Bekaii-Saab T. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol. 2016 Apr; 33(4):37. Epub 2016 Mar 19.
     View PubMed
261. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT, NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6; 387: (10018)545-57.
     View PubMed
262. Ahn DH, Ozer HG, Hancioglu B, Lesinski GB, Timmers C, Bekaii-Saab T. Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors. Oncotarget. 2016 Feb 02; 7: (5)5306-12.
     View PubMed
263. Ahn DH, Bekaii-Saab T. Adjuvant chemotherapy for rectal cancer after neoadjuvant treatment: FOLFOX, 5-FU, or observation Current Colorectal Cancer Reports. 2016; 12: (5)260-5.
     
264. Ahn DH, Williams TM, Goldstein DA, El-Rayes B, Bekaii-Saab T. Adjuvant therapy for pancreas cancer in an era of value based cancer care. Cancer Treat Rev. 2016 Jan; 42: 10-7.
     View PubMed
265. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 1; 22: (1)61-8.
     View PubMed
266. Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T. Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Med Oncol. 2016 Jan; 33: (1)4.
     View PubMed
267. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016 Jan; 27: (1)134-40.
     View PubMed
268. Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer. 2016; 6:21-30.
     View PubMed
269. Brathwaite S, Yearsley MM, Bekaii-Saab T, Wei L, Schmidt CR, Dillhoff ME, Frankel WL, Hays JL, Wu C, Abdel-Misih S. Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry. Front Oncol. 2016; 6:148 Epub 2016 June 13
     View PubMed
270. Mace TA, Shakya R, Elnaggar O, Wilson K, Komar HM, Yang J, Pitarresi JR, Young GS, Ostrowski MC, Ludwig T, Bekaii-Saab T, Bloomston M, Lesinski GB. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Oncotarget. 2015 Dec 29; 6: (42)44509-22.
     View PubMed
271. Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. J Natl Cancer Inst. 2015 Dec; 107: (12)djv274.
     View PubMed
272. Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemother Pharmacol. 2015 Nov; 76: (5)1005-12.
     View PubMed
273. Mikhail S, Bekaii-Saab T. Maintenance therapy for colorectal cancer: which regimen and which patients? Drugs. 2015 Nov; 75: (16)1833-42.
     View PubMed
274. Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J, Elvin JA, Lipson D, Miller VA, Stephens PJ, Ross JS. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist. 2015 Oct; 20: (10)1132-9.
     View PubMed
275. Mikhail S, Ciombor K, Noonan A, Wu C, Goldberg R, Zhao W, Wei L, Mathey K, Yereb M, Timmers C, Bekaii-Saab T. Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet? Oncotarget. 2015 Sep 8; 6: (26)22206-13.
     View PubMed
276. Shaib WL, Goodman M, Chen Z, Kim S, Brutcher E, Bekaii-Saab T, El-Rayes BF. Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. Am J Clin Oncol. 2015 Aug 11;
     View PubMed
277. Wu C, Mikhail S, Wei L, Timmers C, Tahiri S, Neal A, Walker J, El-Dika S, Blazer M, Rock J, Clark DJ, Yang X, Chen JL, Liu J, Knopp MV, Bekaii-Saab T. A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers. Br J Cancer. 2015 Jul 14; 113 (2):220-5 Epub 2015 July 07
     View PubMed
278. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, Phelps MA, Villalona-Calero MA, Bekaii-Saab T. Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep. 2015 Jul 10; 5:12122.
     View PubMed
279. Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W, Marx H, Bekaii-Saab T, Lesinski GB, Swanson B, Sanchez D, Manzanera AG, Aguilar-Cordova E, Bloomston M. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother. 2015 Jun; 64: (6)727-36.
     View PubMed
280. Petullo B, Wei L, Yereb M, Neal A, Rose J, Bekaii-Saab T, Wu C. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. J Gastrointest Oncol. 2015 Jun; 6(3):336-40.
     View PubMed
281. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13 (6):719-28; quiz 728
     View PubMed
282. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015 Apr; 22(4):1153-9. Epub 2014 Oct 31.
     View PubMed
283. Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE 3rd. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immunother. 2015 Feb; 64: (2)149-59.
     View PubMed
284. Noonan AM, Bekaii-Saab T. Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb; 15: (1)133-43.
     View PubMed
285. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7.
     View PubMed
286. Ciombor KK, Bekaii-Saab T. Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan; 24: (1)111-123.
     View PubMed
287. Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A, Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Sci Rep. 2015; 5:10867.
     View PubMed
288. Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel). 2015; 3: (3)519-43.
     View PubMed
289. Yeo H, Niland J, Milne D, ter Veer A, Bekaii-Saab T, Farma JM, Lai L, Skibber JM, Small W Jr, Wilkinson N, Schrag D, Weiser MR. Incidence of minimally invasive colorectal cancer surgery at National Comprehensive Cancer Network centers. J Natl Cancer Inst. 2015 Jan; 107: (1)362.
     View PubMed
290. Nichols SD, Albert S, Shirley L, Schmidt C, Abdel-Misih S, El-Dika S, Groce JR, Wu C, Goldberg RM, Bekaii-Saab T, Bloomston M. Outcomes in patients with obstructive jaundice from metastatic colorectal cancer and implications for management. J Gastrointest Surg. 2014 Dec; 18(12):2186-91. Epub 2014 Oct 10.
     View PubMed
291. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 2014 Oct; 35: (10)2203-13.
     View PubMed
292. Jaremka LM, Andridge RR, Fagundes CP, Alfano CM, Povoski SP, Lipari AM, Agnese DM, Arnold MW, Farrar WB, Yee LD, Carson WE 3rd, Bekaii-Saab T, Martin EW Jr, Schmidt CR, Kiecolt-Glaser JK. Pain, depression, and fatigue: loneliness as a longitudinal risk factor. Health Psychol. 2014 Sep; 33: (9)948-57.
     View PubMed
293. Tejani MA, ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, Schrag D, Shibata S, Skibber J, Weiser M, Wilkinson N, Cohen SJ. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw. 2014 Aug; 12: (8)1123-30.
     View PubMed
294. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2014 Jul 25;
     View PubMed
295. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014 Jul; 16(7):553-7. Epub 2014 Jan 16.
     View PubMed
296. Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Crit Rev Oncol Hematol. 2014 Jul; 91: (1)9-34.
     View PubMed
297. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12: (7)1028-59.
     View PubMed
298. Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23 (7):726-34 Epub 2014 May 16
     View PubMed
299. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120: (12)1780-6.
     View PubMed
300. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, ARIES Study Investigators. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26 (6):323-32 Epub 2014 Mar 28
     View PubMed
301. Mikhail S, Bekaii-Saab T. Antiangiogenics and Metastatic Colorectal Cancer: Who is an Optimal Candidate? Cancer & Chemotherapy Reviews.2014 Apr-Jun;9:(2):
     
302. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab Pancreas.2014 Apr;43:(3):343-9.
     View PubMed
303. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43 (3):343-9
     View PubMed
304. Martin LK, Luu DC, Li X, Muscarella P, Ellison EC, Bloomston M, Bekaii-Saab T. The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experience. Ann Surg Oncol. 2014 Mar; 21: (3)862-7.
     View PubMed
305. Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest New Drugs. 2014 Feb; 32: (1)113-22.
     View PubMed
306. Reyngold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, Lai L, Schrag D, Skibber JM, Small W Jr, Weiser M, Wilkinson N, Goodman KA. Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. J Natl Compr Canc Netw. 2014 Feb; 12: (2)235-43.
     View PubMed
307. Ahn DH, Bekaii-Saab T. Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014; 112-5.
     View PubMed
308. Coburn N, Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardosa R, Mahar A, Lourenco LG, Dixon M, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, McLeod R. Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg. 2014 Jan; 259: (1)102-8.
     View PubMed
309. Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, Seevaratnam R, Cardoso R, McLeod R, Dixon M, Yohanathan L, Lourenco LG, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn NG. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014 Jan; 149: (1)18-25.
     View PubMed
310. Mikhail S, Bekaii-Saab T. RAS mutations: impact on treatment outcome Colorectal Cancer.2013 Dec;2:(6):525-534.
     
311. Haraldsdottir S, Bekaii-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2013 Sep; 4: (3)285-98.
     View PubMed
312. Ciombor KK, Bekaii-Saab T. Emerging treatments in recurrent and metastatic colorectal cancer. J Natl Compr Canc Netw. 2013 Sep; 11 Suppl 4: S18-27.
     View PubMed
313. Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A, Lourenco LG, Yohanathan L, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn N, International multidisciplinary expert panel. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013 Aug; 217: (2)347-57.e1.
     View PubMed
314. Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013 Aug 1; 119: (15)2692-700.
     View PubMed
315. Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol. 2013 Jul 1; 191: (1)217-27.
     View PubMed
316. Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs. 2013 Jun; 31: (3)685-95.
     View PubMed
317. Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezai K, Buchbinder A. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jun; 71: (6)1499-506.
     View PubMed
318. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 2013 May 15; 73: (10)3007-18.
     View PubMed
319. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA, National Comprehensive Cancer Network. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 1; 11: (5)519-28.
     View PubMed
320. Martin LK, Bekaii-Saab T. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. J Natl Compr Canc Netw. 2013 Mar 1; 11: (3)298-307; quiz 307.
     View PubMed
321. Dixon M, Seevaratnam R, Wirtzfeld D, McLeod R, Helyer L, Law C, Swallow C, Paszat L, Bocicariu A, Cardoso R, Mahar A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, Van de Velde CJ, Wong S, Coburn N. A RAND/UCLA appropriateness study of the management of familial gastric cancer. Ann Surg Oncol. 2013 Feb; 20: (2)533-41.
     View PubMed
322. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 1; 11: (2)141-52; quiz 152.
     View PubMed
323. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013 Jan 15; 119: (2)285-92.
     View PubMed
324. Martin LK, Bekaii-Saab T, Serna D, Monk P, Clinton SK, Grever MR, Kraut EH. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors. Onkologie. 2013; 36: (11)657-60.
     View PubMed
325. Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013 Jan; 79: (1)27-32.
     View PubMed
326. Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab T. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer. 2012 Dec 15; 118: (24)6243-52.
     View PubMed
327. Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 1; 10: (12)1528-64.
     View PubMed
328. Martin LK, Wei L, Trolli E, Bekaii-Saab T. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol. 2012 Dec; 29: (5)3101-7.
     View PubMed
329. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer. 2012 Nov 15; 118: (22)5497-506.
     View PubMed
330. Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab T. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84: (4)e475-81.
     View PubMed
331. Martin LK, Otterson GA, Bekaii-Saab T. Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. Photomed Laser Surg. 2012 Nov; 30: (11)668-71.
     View PubMed
332. Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, Bekaii-Saab T. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer. 2012 Sep; 11: (3)195-9.
     View PubMed
333. Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012 May 8; 106: (10)1583-6.
     View PubMed
334. Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs. 2012 Apr; 30: (2)629-38.
     View PubMed
335. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW Jr, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA, National Comprehensive Cancer Network. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10: (4)449-54.
     View PubMed
336. Kaffenberger BH, Bekaii-Saab T. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds. Clin Appl Thromb Hemost. 2012 Jan-Feb; 18: (1)104-6.
     View PubMed
337. Peck J, Wei L, Zalupski M, O'Neil B, Villalona Calero M, Bekaii-Saab T. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012; 82: (3)175-9.
     View PubMed
338. Martin LK, Bekaii-Saab T. Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis. 2012; 2012: 758385.
     View PubMed
339. Blazer M, Phillips G, Reardon J, Efries D, Smith Y, Weatherby L, Juergens K, Rose J, Griffith N, Bekaii-Saab T. Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. Oncology. 2012; 83: (3)135-40.
     View PubMed
340. Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract. 2012; 2012: 359041.
     View PubMed
341. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17: (12)1486-95.
     View PubMed
342. Lin L, Fuchs J, Li C, Olson V, Bekaii-Saab T, Lin J. STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH(+)/CD133(+) stem cell-like human colon cancer cells. Biochem Biophys Res Commun. 2011 Dec 16; 416: (3-4)246-51.
     View PubMed
343. Serna DS, Bekaii-Saab T, Kraut EH. A phase I study of topotecan and gemcitabine in advanced solid tumors. Invest New Drugs. 2011 Dec; 29: (6)1390-4.
     View PubMed
344. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW Jr, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C, National Comprehensive Cancer Network. Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9: (11)1238-90.
     View PubMed
345. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GB. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011 Sep; 60: (9)1269-79.
     View PubMed
346. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10; 29: (17)2357-63.
     View PubMed
347. Ramaswamy B, Mrozek E, Kuebler JP, Bekaii-Saab T, Kraut EH. Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer. Invest New Drugs. 2011 Apr; 29: (2)347-51.
     View PubMed
348. Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol. 2011 Mar; 67: (3)511-7.
     View PubMed
349. Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov; 66: (6)1019-29.
     View PubMed
350. Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 May; 66: (1)151-8.
     View PubMed
351. Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol. 2010 May; 5 (5):713-8
     View PubMed
352. Bekaii-Saab T, Hill M, Campbell A, Kosuri K, Thomas J, Villalona-Calero M. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Cancer Chemother Pharmacol. 2010 Apr; 65: (5)863-9.
     View PubMed
353. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8: (4)378-409.
     View PubMed
354. Ntukidem N, Arce-Lara C, Otterson GA, Kraut E, Cataland S, Bekaii-Saab T. Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. Cancer Chemother Pharmacol. 2010 Jan; 65: (2)319-24.
     View PubMed
355. O'Reilly EM, Niedzwiecki D, Hall M, Hollis D, Bekaii-Saab T, Pluard T, Douglas K, Abou-Alfa GK, Kindler HL, Schilsky RL, Goldberg RM, Cancer and Leukemia Group B. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15: (12)1310-9.
     View PubMed
356. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15; 15: (18)5895-901.
     View PubMed
357. Friedman L, Lin L, Ball S, Bekaii-Saab T, Fuchs J, Li PK, Li C, Lin J. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anticancer Drugs. 2009 Jul; 20: (6)444-9.
     View PubMed
358. Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. Clin Colorectal Cancer. 2009 Jul; 8: (3)135-40.
     View PubMed
359. Bekaii-Saab T. Expanding the arsenal for metastatic colorectal cancer: a discussion of current clinical trials. Clin Adv Hematol Oncol. 2009 Jul; 7: (7)430-2.
     View PubMed
360. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Esophageal Cancer Panel. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6: (9)818-49.
     View PubMed
361. Haghighat P, Bekaii-Saab T. An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. J Natl Compr Canc Netw. 2008 Oct; 6: (9)895-900.
     View PubMed
362. Bekaii-Saab TS, Liu J, Chan KK, Balcerzak SP, Ivy PS, Grever MR, Kraut EH. A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors. Clin Cancer Res. 2008 Jun 01; 14 (11):3434-40
     View PubMed
363. Kapoor KG, Bekaii-Saab T. Warfarin-Induced Allergic Interstitial Nephritis and Leukocytoclastic Vasculitis Intern Med J.2008 Apr;38:(4):281-3.
     
364. So BJ, Bekaii-Saab T, Bloomston MA, Patel T. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 2008; 1:18.
     View PubMed
365. Ross P Jr, Grecula J, Bekaii-Saab T, Villalona-Calero M, Otterson G, Magro C. Incorporation of photodynamic therapy as an induction modality in non-small cell lung cancer. Lasers Surg Med. 2006 Dec; 38: (10)881-9.
     View PubMed
366. Benson AB 3rd, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA Jr, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ, National Comprehensive Cancer Network. Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Sep; 4: (8)728-50.
     View PubMed
367. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4: (4)328-47.
     View PubMed
368. Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4: (4)350-66.
     View PubMed
369. Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer. 2006; 6:278.
     View PubMed
370. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther. 2004 Aug; 310: (2)656-65.
     View PubMed
371. Bekaii-Saab T, Einhorn LH, Williams SD. Late Relapse of Ovarian Dysgerminoma: Case Report and Literature Review Gynecologic Oncology.1999;72:111-112.